Latest Headlines

Latest Headlines

AstraZeneca trumpets diabetes duo's victory in Phase III

While its top executives were prepping for a hearing on Pfizer's megamerger offer, AstraZeneca rolled out new data from a diabetes trial. The verdict? A combination of the company's two diabetes pills, Onglyza and Farxiga, bested either drug alone.

AstraZeneca touts arthritis, lupus data with a rosy view of its pipeline

Two key investigational drugs came through in mid-stage studies, providing some ballast for the drugmaker as it boasts the value of its pipeline in an effort to ward off an unwelcome bid by Pfizer--or at least drive up the asking price.

Today's need-to-know on the Pfizer-AstraZeneca drama? It's all right here

Another day, another onslaught of Pfizer-AstraZeneca news. We admit to a slight case of Pfizer Pfatigue, and if yesterday's web traffic is any guide, readers are similarly afflicted. But the $100 billion-plus merger proposal is massive, with enormous potential side effects, so even the rhetoric is worth consideration. Here are the highlights, from hints of a new bid to Pfizer CEO Ian Read's purported reassurances to U.S. lawmakers' heightened job worries.

Pfizer's quest for AstraZeneca becomes political theater as MPs probe $106B offer

The leaders of Pfizer and AstraZeneca are taking turns making their cases to British lawmakers, with the former trying to mollify locals afraid that its planned $106 billion buyout would maim U.K. R&D and the latter working to mount a defense in its home country.

Biochips, bioprinting offer alternative drug testing options

New technology like organs-on-chips and bioprinted tissues have the potential to test the safety of drugs more accurately and cost-efficiently for a myriad of diseases. FierceBiotech Research highlights some organizations that are working on alternative drug testing technology.

Pfizer makes a case for R&D in AstraZeneca megamerger, but does anyone believe it?

With various U.K. media groups adding their voices to a crescendo of criticism over Pfizer's proposed $106 billion-plus buyout of AstraZeneca, the company's R&D chief is continuing to try and insist that this deal makes really good sense from a drug research perspective. But he's finding few buyers for that argument after years of Big Pharma reorganizations and mass layoffs in R&D.

Parsing Pfizer's deal talk isn't an exercise. It's the tell on AstraZeneca's future

With U.K. lawmakers skeptical of Pfizer's commitment to keep AstraZeneca jobs and AstraZeneca science in the U.K., Pfizer over the weekend released a series of videos focusing on that science--and downplaying the tax benefits CEO Ian Read crowed about so loudly when first confirming his company's trans-Atlantic bid.

Show me the money: Which drugs made the top 10 list on upfront deals?

Given the eyebrow-raising cash component in Celgene's new deal with Nogra, we thought it would be fun to list the top 10 upfronts paid for experimental drugs, ranked simply according to the cash included in the upfront--no surer sign of what a company really thinks about the potential of an experimental therapy or portfolio.

Amgen, AstraZeneca score a PhIII psoriasis success with brodalumab

After the markets closed Friday, Amgen and AstraZeneca announced that their top psoriasis contender, brodalumab, scored a win in Phase III, with a large majority of patients in both dosage arms clearing the bar on a standard measure for efficacy.

Pfizer's move on AstraZeneca outrages pols on two continents

Pfizer has managed to upset just about everybody with its $106 billion takeover offer for U.K.-based AstraZeneca. AstraZeneca doesn't like it. The U.K. Parliament is concerned about possible losses of job and status. Some U.S. politicians see it as a tax dodge, and even a couple of governors fear Pfizer will slash AstraZeneca jobs in their states.